Neximmune announces pricing of upsized initial public offering

Gaithersburg, md., feb. 11, 2021 (globe newswire) -- neximmune, inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own t cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share. the gross proceeds to neximmune from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $110 million. all of the shares are being offered by neximmune. in addition, neximmune has granted the underwriters a 30-day option to purchase up to an additional 970,650 shares of common stock at the initial price to the public less underwriting discounts and commissions.
NEXI Ratings Summary
NEXI Quant Ranking